Integrated capabilities Aurigene offers end-to-end services across medicinal chemistry, biology, preclinical, DMPK, development and manufacturing for clinical to commercial scale, plus integrated API and formulations. This enables a single partner for discovery through to manufacturing, presenting a sales opportunity for a broad outsourcing mandate.

Global manufacturing footprint cGMP facilities in the UK, US, Mexico and India, complemented by a strong discovery-to-development capability in India, position Aurigene to handle multi-region programs and regulatory filings, appealing to customers seeking regional manufacturing access and supply chain resilience.

Biologics expansion Recent $40M investment to launch a 70,000 sq ft biologics facility in Hyderabad expands end-to-end services from discovery to commercial manufacturing, offering upsell opportunities to clients planning biologics or hybrid modalities.

Strategic partnerships Active collaborations and non-binding MoUs with Kainomyx for anti-malarial programs and Edity Therapeutics for advanced therapies demonstrate a momentum in partnering for novel technologies, signaling openness to co-development models and expanding addressable markets.

Innovation enablement Access to CRISPR/Cas9 patent portfolio via ERS Genomics and adoption of diverse tech stack (Grafana, Kafka, Docker, cloud, and DevOps tools) indicate a differentiated capability in cutting-edge discovery platforms, creating conversations around faster molecule-to-market timelines.